BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Phase 3positiveVOXZOGOPositive
AI Analysis
Summary
BioMarin announced positive Phase 3 CANOPY-HCH-3 results for VOXZOGO (vosoritide) in hypochondroplasia, with statistically significant improvements across multiple endpoints. Data were published in NEJM Evidence and presented at ESPE 2026 Annual Meeting.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
statistically significant improvements across multiple endpoints
Importance:8/10
Sentiment:
0.85
Phase 3 dataVOXZOGOhypochondroplasiaNEJM Evidence publicationESPE 2026 presentationpositive results
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 1:05 PM